RxDoctor Payments Data

Muhammad Asad, MD

Interventional Cardiology · Hermitage, TNNPI 1275536468

Payments from drug & device makers

$13,593in general payments, 2019–2025

Across 669 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$919
  • Novo Nordisk$908
  • Boston Scientific$887
  • Johnson & Johnson$886
  • plus $7K from 46 others

What the payments were for

  • Food & beverage$13,49199%
  • Education$1011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,593 in reported general payments places this provider in the 60th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$206,712
Medicare patients
1,441
Services billed
3,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban299$317,633
XareltoRivaroxaban171$191,872
JardianceEmpagliflozin157$166,564
OzempicSemaglutide78$115,897
EntrestoSacubitril/Valsartan70$91,993
Repatha SureclickEvolocumab108$90,086
WegovySemaglutide21$29,658
FarxigaDapagliflozin Propanediol21$26,376
VerquvoVericiguat22$23,228
MounjaroTirzepatide14$16,641
Repatha SyringeEvolocumab13$12,476
Praluent PenAlirocumab15$10,893
Ezetimibe309$8,388
BrilintaTicagrelor14$7,799
Atorvastatin Calcium570$6,722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$919$317,633299 claims
Johnson & JohnsonXarelto$886$191,872171 claims
Boehringer IngelheimJardiance$827$166,564157 claims
Novo NordiskOzempic, Wegovy$908$145,55699 claims
NovartisEntresto$512$91,99370 claims
AstraZenecaFarxiga, Brilinta$524$34,17635 claims
MerckVerquvo$445$23,22822 claims
Lilly USA, LLCMounjaro$75$16,64114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Hermitage

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →